Current tests to evaluate HIV-1 coreceptor tropism

Purpose of reviewHIV-1 entry into target cells is a complex multistage process involving the envelope glycoprotein, primary cellular receptor CD4, and at least two main cellular coreceptors, CCR5 and CXCR4. The identification of the HIV-1 coreceptors led to the rapid development of several drug candidates that selectively block this interaction, that is, CCR5 or CXCR4 antagonists. Here, we review different methodologies used to determine the ability of the virus to use one or both coreceptors and their potential role in managing HIV-infected individuals treated with these novel drugs. Recent findingsMost commercially available HIV-1 tropism assays are cell-based (phenotypic) tests, which use different methodologies to generate env-recombinant viruses and distinct detection systems. On the other hand, a large effort is being devoted to develop more robust bioinformatic (genotypic) tools that may expedite HIV-1 tropism assays without compromising their accuracy. The main goal, however, continues to be to improve the sensitivity to detect minor CXCR4-tropic variants within the in-vivo HIV-1 quasispecies. SummaryAn accurate determination, and perhaps quantification, of HIV-1 coreceptor usage is necessary for the successful management of HIV-infected individuals in the new era of entry inhibitors. Further studies, aimed to the development of novel methodologies, are essential for the success of this new class of drugs.

[1]  S. Norley,et al.  Characterization of a chemokine receptor CCR5‐negative T cell line and its use in determining human immunodeficiency virus type 1 phenotype , 2008, Journal of medical virology.

[2]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[3]  C. Petropoulos,et al.  Coreceptor Tropism Can Be Influenced by Amino Acid Substitutions in the gp41 Transmembrane Subunit of Human Immunodeficiency Virus Type 1 Envelope Protein , 2008, Journal of Virology.

[4]  H. Schuitemaker,et al.  Relation of phenotype evolution of HIV-1 to envelope V2 configuration. , 1993, Science.

[5]  Gabriella Scarlatti,et al.  Determination of Coreceptor Usage of Human Immunodeficiency Virus Type 1 from Patient Plasma Samples by Using a Recombinant Phenotypic Assay , 2001, Journal of Virology.

[6]  Andrew J. Low,et al.  Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates , 2007, Antiviral therapy.

[7]  L. Scudeller,et al.  HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples. , 2007, Virus research.

[8]  E. Poveda,et al.  Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters , 2008, Journal of Acquired Immune Deficiency Syndromes.

[9]  J. Albert,et al.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.

[10]  J. Albert,et al.  Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates, Like HIV-1 Isolates, Frequently Use CCR5 but Show Promiscuity in Coreceptor Usage , 1999, Journal of Virology.

[11]  Eoin Coakley,et al.  Assessing chemokine co-receptor usage in HIV , 2005, Current opinion in infectious diseases.

[12]  L. Stuyver,et al.  HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. , 2007, Journal of virological methods.

[13]  H. Whittle,et al.  Development of a one-tube multiplex reverse transcriptase-polymerase chain reaction assay for the simultaneous amplification of HIV type 1 group M gag and env heteroduplex mobility assay fragments. , 2000, AIDS research and human retroviruses.

[14]  H. Schuitemaker,et al.  Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR , 1995, Journal of clinical microbiology.

[15]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[16]  R. Coutinho,et al.  HIV‐1 biological phenotype in long‐term infected individuals evaluated with an MT‐2 cocultivation assay , 1992, AIDS.

[17]  J. Albert,et al.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates , 1988, Journal of virology.

[18]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[19]  J. Goudsmit,et al.  Determinants for the syncytium-inducing phenotype of HIV-1 subtype F isolates are located in the V3 region. , 2000, AIDS research and human retroviruses.

[20]  Natalia Chueca,et al.  Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes , 2008, Journal of Clinical Microbiology.

[21]  H. Schuitemaker,et al.  Determination of co-receptor usage of HIV-1. , 2005, Methods in molecular biology.

[22]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[23]  Tobias Sing,et al.  Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates , 2007, AIDS.

[24]  V. Trouplin,et al.  Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors , 2003, Journal of Virology.

[25]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[26]  F. Brun-Vézinet,et al.  V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. , 1996, AIDS research and human retroviruses.

[27]  Tobias Sing,et al.  Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model , 2006, Journal of Clinical Microbiology.

[28]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[29]  B. Levine,et al.  Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. , 1997, Science.

[30]  L. Stamatatos,et al.  Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor , 1997, Journal of virology.

[31]  D. Richman,et al.  A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. , 1993, The Journal of infectious diseases.

[32]  J. Levy.  Pathogenesis of human immunodeficiency virus infection , 1989, Microbiological reviews.

[33]  H. Schuitemaker,et al.  Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.

[34]  Q. Sattentau,et al.  The History of HIV-1 Biological Phenotypes Past , Present and Future , 1998 .

[35]  C. Cheng‐Mayer,et al.  Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 , 1991, Journal of virology.

[36]  Robert Blumenthal,et al.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Helen Piontkivska,et al.  HIV type 1 tropism and inhibitors of viral entry: clinical implications. , 2006, AIDS reviews.

[38]  C. Cheng‐Mayer,et al.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation , 1990, Journal of virology.

[39]  H. Schuitemaker,et al.  Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain , 1992, Journal of virology.

[40]  Lange,et al.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates , 1989, Journal of virology.

[41]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[42]  L. Cuzin,et al.  Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism , 2008, AIDS.

[43]  B. Cullen,et al.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. , 1991, Science.

[44]  Thomas Lengauer,et al.  Structural Descriptors of gp120 V3 Loop for the Prediction of HIV-1 Coreceptor Usage , 2007, PLoS Comput. Biol..

[45]  Noah G. Hoffman,et al.  Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.

[46]  Andreas Meyerhans,et al.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations , 1989, Cell.

[47]  J. Albert,et al.  Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. , 2001, AIDS research and human retroviruses.

[48]  J. Goudsmit,et al.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity , 1992, Journal of virology.

[49]  M. Jensen,et al.  Predicting HIV-1 coreceptor usage with sequence analysis. , 2003, AIDS reviews.

[50]  A. Cann,et al.  A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism , 1993, Journal of virology.

[51]  E. De Clercq,et al.  Coreceptor Phenotype of Natural Human Immunodeficiency Virus with Nef Deleted Evolves In Vivo, Leading to Increased Virulence , 2002, Journal of Virology.

[52]  B. Margolin,et al.  V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability , 1993, Journal of virology.

[53]  A. Trkola,et al.  Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage , 1998, Journal of Virology.

[54]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[55]  Carlos Toro,et al.  Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failure , 2004, Journal of medical virology.

[56]  J. Albert,et al.  Replicative capacity, cytopathic effect and cell tropism of HIV , 1989, AIDS.

[57]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.

[58]  Christos J. Petropoulos,et al.  Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.

[59]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[60]  E. Poveda,et al.  HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors , 2006, AIDS.

[61]  John P. Moore,et al.  Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells , 2000, Journal of Virology.

[62]  S. Bartz,et al.  Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. , 1997, Virology.

[63]  A. Osterhaus,et al.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation , 1993, Journal of virology.

[64]  Y. Soda,et al.  Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. , 1999, Biochemical and biophysical research communications.

[65]  G. Fogel,et al.  Prediction of R5, X4, and R5X4 HIV-1 Coreceptor Usage with Evolved Neural Networks , 2008, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[66]  Jacques Corbeil,et al.  A new perspective on V3 phenotype prediction. , 2003, AIDS research and human retroviruses.

[67]  J. Levy,et al.  HIV and the Pathogenesis of AIDS , 1994, Nature Medicine.

[68]  P. Piot,et al.  Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. , 1995, AIDS research and human retroviruses.